Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q1 2017 · 10-Q
Revenue$10.38M$10.38M+27.9% vs Q1 2016 Net Income-$23.09M-$23.09MN/M vs Q1 2016 EPS Diluted-$0.31-$0.31N/M vs Q1 2016 Operating Income-$21,933,908N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
Free Cash Flowderived-$16,016,697N/M Margins · derivedOperating margin-211.4%−20.9 pt vs Q1 2016
Net margin-222.5%−123.3 pt vs Q1 2016
ended Mar 31, 2017 · filed May 10, 2017 · 40 d after period end